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Abstract 
Our results show that using an EBV-LCL feeder cell line, large numbers of pure popula-
tions of highly activated NK cells can be expanded ex vivo under GMP conditions. With 
the exception of thyroiditis and constitutional symptoms related to IL-2 therapy, infu-
sions of up to 1 x 108 cells/kg of ex vivo expanded NK have been well tolerated and have 
provided preliminary clinical evidence for mediating anti-tumor immunity in patients 
with advanced cancer. 
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Natural killer (NK) cells are innate lymphocytes 
which  have  the  capacity  to  kill  tumor  cells.  Unlike 
antigen specific T cells, NK cells do not require the 
presence of a specific tumor antigen for the recogni-
tion and killing of cancer cells. NK cell recognition of 
tumor targets is regulated through a balance of acti-
vating and inhibitory signals 1. Even in the presence of 
an  activating  ligand,  inhibitory  ligands  can  initiate 
overriding signals that culminate in a net suppression 
of NK cell function. The inactivation of NK cells by 
self-HLA  molecules  is  a  potential  mechanism  by 
which malignant cells evade host NK cell-mediated 
immunity. This may limit the ability of both endoge-
nous and adoptively infused autologous NK cells to 
induce antitumor effects against tumors.  
In humans, pilot studies have shown that adop-
tive transfer of IL-2-activated KIR- incompatible NK 
cells can be associated with responses in patients with 
a variety of malignancies 1,2,3. Despite these observa-
tions, the therapeutic potential of NK cell-based im-
munotherapy remains largely unknown. Adoptively 
infused allogeneic KIR incompatible NK cells could be 
used in the setting of an allogeneic HCT as a method 
to  enhance  graft-vs-tumor  effects  against  RCC  and 
other cancers 4,5. However, because mismatched MHC 
molecules would eventually lead to their rejection by 
the patient’s immune system, outside the setting of an 
allogeneic  transplant,  KIR-ligand  mismatched  NK 
cells would potentially be of limited therapeutic effi-
cacy. To offset the need for allogeneic KIR incompati-
ble NK cells, we have explored various methods to 
potentiate autologous NK cell killing of tumor cells.   
NK cells lyse tumor targets directly via the per-
forin/granzyme pathway. They also express Fas lig-
and  and  tumor  necrosis  factor-related  apopto-
sis-inducing  ligand  (TRAIL),  which  directly  trigger 
death receptor pathways inducing tumor apoptosis. 
Recently,  we  found  that  the  proteosome  inhibitor 
bortezomib  sensitized  tumors  to  NK  cell  killing  6. 
Remarkably, NK cells expanded from patients with 
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metastatic  RCC  were  significantly  more  cytotoxic 
against  the  patient’s  own  autologous  tumor  cells 
when tumors were pretreated with bortezomib com-
pared  to  untreated  tumors.  The  enhanced  NK  cell 
killing  effect  was  found  to  be  dependent  on  the 
up-regulation of receptors on the tumor surface for 
tumor necrosis factor related apoptosis inducing lig-
and  (TRAIL)  and  to  drug-induced  augmentation  of 
tumor caspase-8 activity, leading to enhanced tumor 
killing  via  perforin/granzyme  mediated  NK-tumor 
cytotoxicity. Tumors sensitized to NK cell cytotoxicity 
showed a significant increase in surface expression of 
DR5 (TRAIL-R2) and enhanced susceptibility to NK 
cell  killing  was  completely  abolished  by  blocking 
TRAIL on NK cells and partially abolished by block-
ing DR5 on tumor cells. Remarkably, non-malignant 
cells including hematopoietic cells and fibroblasts did 
not  show  enhanced  susceptibility  to  killing  by  NK 
cells or recombinant TRAIL after exposure to either of 
these  agents  suggesting  that  this  sensitizing  effect 
may be specific to malignant cells.   
Murine studies conducted in our lab have shown 
that bortezomib also augments the anti-tumor effects 
of syngeneic NK cell infusions in tumor-bearing ani-
mals with this effect being further enhanced by regu-
latory T-cell (Treg) depletion 7,8.   
Based  on  these  preclinical  data,  a  clinical  trial 
was initiated to explore the safety and antitumor ef-
ficacy  of  escalating  doses  of  adoptively  infused  ex 
vivo expanded autologous NK cells following borte-
zomib  treatment  in  patients  with  advanced  malig-
nancies 9. Patients age 18-70 with chronic lymphocytic 
leukemia or a variety of different metastatic tumors 
with  progressive  disease  refractory  to  conventional 
therapy were eligible for study. Patients underwent 
an  apheresis  to  isolate  NK  cells  that were  enriched 
using  immuno-magnetic  beads  to  deplete  CD3+ 
T-cells  followed  by  CD56+  selection.  Enriched  NK 
cells were expanded in vitro over 2 weeks using an 
irradiated  clinical  grade  EBV  transformed  lympho-
blastoid cell line10. Three days prior to NK cell infu-
sion, subjects received a single injection of pentostatin 
(4mg/m2) to deplete regulatory T-cells followed by a 
single injection of bortezomib (1.3 mg/m2) one day 
prior to the infusion of autologous ex vivo expanded 
NK cells given on day 0. To maintain NK cell viability 
and  TRAIL  surface  expression,  2  million  IU/m2  of 
IL-2 was given s.c. every 12 hours for 7 days. Patients 
were restaged at 3 weeks and those with disease re-
gression or stable disease were eligible to receive ad-
ditional cycles. Cohorts of 3-6 pts have been enrolled 
into  escalating  NK  cell  dose  levels  (5  x  106,  1x  107, 
5x107,  and  1x108 NK  cells/kg).    For  cohorts  1-4,  14 
patients were received a total of 43 NK cell infusions.  
Following a 2 week culture, NK cells expanded a me-
dian 184 fold (range 58-683) with 42/43 cultures ex-
panding  successfully  to  achieve  the  target  NK  cell 
dose. NK cells harvested a median 14 days after ex-
pansion  (range  14-16)  contained  a  median  99.7% 
(range  96-100)  CD3-/CD56+  NK  cells,  0%  CD3+ 
T-cells and had a median 87% (range 71-93) viability 
by 7AAD/Annexin V staining.   
The  most  common  adverse  events  related  to 
treatment  were  attributable  to  IL-2  therapy  and  in-
cluded  grades  I-II  fever,  renal  insufficiency,  edema 
and hypotension. Two pts developed laboratory evi-
dence  for  acute  thyroiditis  with  one  subsequently 
developing  hypothyroidism  requiring  thyroid  re-
placement  therapy.    The  best  clinical  response  ob-
served to date has included 7/14 patients having sta-
ble disease including two patients who had more than 
a 30% decline in serum tumor markers and 1 patient 
with metastatic kidney cancer who has had a minor 
response. NK cell cohorts 1-4 have established that a 
single  infusion  of  autologous  NK  cells  following 
bortezomib treatment is safe (i.e. a dose limiting tox-
icity  was  not  reached  in  cohorts  1-4).  Our  animal 
models using sequential bioluminescence imaging to 
determine tumor burden have shown that maximum 
anti-tumor  effects  and  prolongation  of  survival  are 
observed  in  tumor  bearing  mice  that  received  re-
peated  infusions  of  NK  cells  following  bortezomib 
treatment 7. Therefore, we added additional cohorts to 
this ongoing phase I study to evaluate the safety of 
escalating doses of a second NK cell infusion given 
with each treatment cycle.   
In conclusion, these results show that using an 
EBV-LCL feeder cell line, large numbers of pure pop-
ulations of highly activated NK cells can be expanded 
ex vivo under GMP conditions. With the exception of 
thyroiditis  and  constitutional  symptoms  related  to 
IL-2 therapy, infusions of up to 1 x 108 cells/kg of ex 
vivo expanded NK have been well tolerated and have 
provided preliminary clinical evidence for mediating 
anti-tumor immunity in patients with advanced can-
cer.  Once the maximum achievable dose of ex vivo 
expanded  cells  that  can  be  infused  safely  is  estab-
lished, phase II trials in specific tumor subtypes may 
be  initiated  to  establish  overall  efficacy  of  this  ap-
proach.  
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